358 related articles for article (PubMed ID: 38275876)
1. Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma.
Abdel-Rahman SA; Gabr M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275876
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities.
Wang G; Zhong K; Wang Z; Zhang Z; Tang X; Tong A; Zhou L
Front Immunol; 2022; 13():964898. PubMed ID: 35967394
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
4. PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment.
Yang M; Wang B; Yin Y; Ma X; Tang L; Zhang Y; Fan Q; Yin T; Wang Y
J Control Release; 2023 Jan; 353():63-76. PubMed ID: 36402232
[TBL] [Abstract][Full Text] [Related]
5. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy.
Khan F; Pang L; Dunterman M; Lesniak MS; Heimberger AB; Chen P
J Clin Invest; 2023 Jan; 133(1):. PubMed ID: 36594466
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy.
Zhou Y; Guo Y; Chen L; Zhang X; Wu W; Yang Z; Li X; Wang Y; Hu Z; Wang Z
Theranostics; 2022; 12(12):5488-5503. PubMed ID: 35910792
[No Abstract] [Full Text] [Related]
7. Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma.
Jiang S; Li W; Yang J; Zhang T; Zhang Y; Xu L; Hu B; Li Z; Gao H; Huang Y; Ruan S
ACS Nano; 2024 Feb; 18(8):6445-6462. PubMed ID: 38358804
[TBL] [Abstract][Full Text] [Related]
8. Ferritin light chain promotes the reprogramming of glioma immune microenvironment and facilitates glioma progression.
Li H; Yang C; Wei Y; Li X; Jiang W; Xu Y; Li L; Guo R; Chen D; Gao P; Zhang H; Qin H; Zhang Z; Liu X; Yan D
Theranostics; 2023; 13(11):3794-3813. PubMed ID: 37441589
[No Abstract] [Full Text] [Related]
9. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
10. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
Tang L; Zhang M; Liu C
Front Immunol; 2022; 13():882257. PubMed ID: 35651605
[TBL] [Abstract][Full Text] [Related]
11. Multiple Synergistic Effects of the Microglia Membrane-Bionic Nanoplatform on Mediate Tumor Microenvironment Remodeling to Amplify Glioblastoma Immunotherapy.
Fan Q; Kuang L; Wang B; Yin Y; Dong Z; Tian N; Wang J; Yin T; Wang Y
ACS Nano; 2024 May; ():. PubMed ID: 38770948
[TBL] [Abstract][Full Text] [Related]
12. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
14. The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma.
Zhang L; Jiang Y; Zhang G; Wei S
Front Immunol; 2023; 14():1238233. PubMed ID: 37731483
[TBL] [Abstract][Full Text] [Related]
15. Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy.
Collado J; Boland L; Ahrendsen JT; Miska J; Lee-Chang C
Front Immunol; 2024; 15():1336476. PubMed ID: 38380331
[TBL] [Abstract][Full Text] [Related]
16. GBM Immunotherapy: Macrophage Impacts.
Loginova N; Aniskin D; Timashev P; Ulasov I; Kharwar RK
Immunol Invest; 2024 Apr; ():1-22. PubMed ID: 38634572
[TBL] [Abstract][Full Text] [Related]
17. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
[TBL] [Abstract][Full Text] [Related]
18. Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow-Derived Macrophages.
Wu M; Wu L; Wu W; Zhu M; Li J; Wang Z; Li J; Ding R; Liang Y; Li L; Zhang T; Huang B; Cai Y; Li K; Li L; Zhang R; Hu B; Lin F; Wang X; Zheng S; Chen J; You Y; Jiang T; Zhang J; Chen H; Wang Q
Cancer Res; 2023 Mar; 83(5):771-785. PubMed ID: 36622331
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition.
Rao R; Han R; Ogurek S; Xue C; Wu LM; Zhang L; Zhang L; Hu J; Phoenix TN; Waggoner SN; Lu QR
Neuro Oncol; 2022 Apr; 24(4):584-597. PubMed ID: 34562087
[TBL] [Abstract][Full Text] [Related]
20. Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?
Giles B; Nakhjavani M; Wiesa A; Knight T; Shigdar S; Samarasinghe RM
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
